Human Papillomavirüs DNA Pozitif ve E6/E7 mRNA Negatif, Anormal Sitolojili Servikal Örneklerin Genotiplendirilmesi§

Kaynakça (7)

1. Buttmann-Schweiger N, Deleré Y, Klug SJ, Kraywinkel K. Cancer incidence in Germany attributable to human papillomavirus in 2013. BMC Cancer. 2017;17(1):682.
2. Li P, Tan Y, Zhu L, et al. Prognostic value of HPV DNA status in cervical cancer before treatment: a systematic review and meta-analysis. Oncotarget. 2017;8(39): 66352-9.
3. Tsakogiannis D, Gartzonika C, Levidiotou-Stefanou S, Markoulatos P. Molecular approaches for HPV genotyping and HPV-DNA physical status. Expert Rev Mol Med. 2017;19:e1.
4. Morris BJ. Cervical human papillomavirus screening by PCR: advantages of targeting the E6/E7 region. Clin Chem Lab Med. 2005;43(11):1171-7.
5. Lagheden C, Eklund C, Lamin H, et al. Nationwide comprehensive human papillomavirus (HPV) genotyping of invasive cervical cancer. Br J Cancer. 2018;118(10):1377-81.
6. Gravitt PE, Peyton CL, Alessi TQ, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol. 2000;38(1):357-61
7. Hwang T. Detection and typing of human papillomavirus DNA by PCR using consensus primers in various cervical lesions of Korean woman. J Korean Med Sci. 1999;14(6):593-9. https://doi.org/10.3346/jk